Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

British Journal of Clinical Pharmacology

Volumn 45, Issue 6, 1998, Pages 583-590

  Muck W ^a   Unger, S ^a   Kawano, K ^b   Ahr, G ^a  

^a BAYER AG   (Germany)

^b BAYER YAKUHIN LTD   (Japan)

Author keywords

Black; Caucasians; Cerivastatin; Ethnic groups; HMG CoA reductase inhibitor; Japanese; Pharmacokinetics

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; ASIAN; CAUCASIAN; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; ETHNIC DIFFERENCE; HUMAN; JAPAN; MALE; NEGRO; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CONTINENTAL POPULATION GROUPS; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES;

EID: 0031840926     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00717.x     Document Type: Article

References (32)

1. Kawano K, Mück W, Ahr G, Matsuki T. No interethnic difference in the pharmacokinetics of cerivastatin sodium, a novel antihyperlipidemic agent. Jpn J Clin Pharmacol Ther 1997; 28: 335-336.
2. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350-373.
3. The relevance of ethnic factors in the clinical evaluation of medicines, eds Walker S, Lumley C, McAuslane N, London: Kluwer Academic Publishers, 1994.
4. Naito C. Ethnic differences on pharmacokinetic parameters. In The relevance of ethnic factors in the clinical evaluation of medicines, eds Walker S, Lumley C, McAuslane N, London: Kluwer Academic Publisher, 1994: 161-178.
5. Brosen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220-239.
6. Angerbauer R, Bischoff H, Steinke W, Ritter W. BAY w 6228. Drugs Future 1994; 19: 537-541.
7. Stein E, Sprecher D, Allenby KS, et al. Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997; 2: 7-16.
8. Ritter W, Frey R, Krol G, Kuhlmann J. Rivastatin single dose pharmacokinetics. Clin Pharmacol Ther 1993; 53: 210.
9. Mazzu A, Lettieri J, Kaiser L, Frey R, Heller AH. Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 1993; 53: 230.
10. Mück W, Ritter W, Ochmann K, Kuhlmann J. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol 1997; 35: 255-260.
11. Mazzu A, Lettieri J, Heller AH. Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Atherosclerosis 1997; 130 (suppl): S29.
12. Mazzu A, Lettieri J, Kaiser L, Heller AH. A multiple-dose study on the safety and pharmacokinetics of cerivastatin in young and elderly male volunteers. Atherosclerosis 130 (suppl): S29.
13. Stein EA, Isaacsohn J, Zinny M, Mazzu A, Lettieri J, Heller AH. Pharmacokinetics, safety and tolerability of multiple-dose cerivastatin in males and females: a double-blind study. Atherosclerosis 130 (suppl): S33.
14. Steinke W, Yamashita S, Tabei M, et al. Cerivastatin, a new inhibitor of HMG-CoA reductase. Pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996; 24 (suppl.9): 1217-1237.
15. 14C]BAY w 6228: Biotransformation in human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997; 25: 321-331.
16. Radtke M, Göller G. Mück W, Rohde G, Wingender W, Kuhlmann J. Biotransformation and metabolic disposition of cerivastatin in humans. Drug Metab Dispos 1998; in press.
17. Azuma J. Phase I study of an antihyperlipidaemic BAY w 6228 (cerivastatin sodium) (1): Results of single administration studies in healthy adult male volunteers. Jpn Pharmacol Ther 1996; 24(suppl.9): 29-36.
18. Azuma J. Phase I study of an antihyperlipidaemic BAY w 6228 (cerivastatin sodium) (2): Results of multiple administration studies in healthy adult male volunteers. Jpn Pharmacol Ther 1996; 24(suppl.9): 37-53.
19. Vormfelde S, Freudenthaler S, Mück W, et al. Excretion of cerivastatin, an inhitor of the HMG-CoA reductase: no need for dose adjustment in renal dysfunction. Eur J Clin Pharmacol 1997; 52(suppl.): A 163.
20. Schall R, Mueller FO, Hundt HK, et al. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol 1995; 35: 306-313.
21. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 1997; 35: 261-264.
22. Mück W, Ritter W, Frey R, Wetzelsberger N, Lücker PW, Kuhlmann J. Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 1997; 35: 250-254.
23. Lettieri J, Krol G, Mazzu A, Fiebach MZ, Heller AH. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis 130 (suppl): S29.
24. Krol GJ, Beck GW, Ritter W, Lettieri JT. LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm & Biomed Anal 1993; 11: 1269-1275.
25. Mück W, Tanaka T, Ahr G, Kuhlmann J. No interethnic differences in stereoselective disposition of oral nimodipine between Caucasian and Japanese subjects. Int J Clin Pharmacol Ther 1996; 34: 163-171.
26. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability of nifedipine pharmacokinetics and pharmacodynamics: a new oxidation polymorphism in man. Biochem Pharamcol 1984; 33: 3721-3724.
27. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipme plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988; 37: 2507-2510.
28. Renwick AG, Robertson DRC, Macklin B, Challenor V, Waller DG, George CF. The pharmacokinetics of oral nifedipine - a population study. Br J Clin Pharmacol 1988; 25: 701-708.
29. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329-338.
30. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995; 40: 489-493.
31. Lindholm A, Welsh M, Alton C, Kaban BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359-371.
32. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin pre- and co-treatment on the single-dose pharmacokinetics of cerivastatin. Eur J Clin Pharmacol 1998; 53: 469-473.